From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery

被引:10
|
作者
Ferreira, Leonardo G. [1 ]
Andricopulo, Adriano D. [1 ]
机构
[1] Univ Sao Paulo, Inst Fis Sao Carlos, Ctr Pesquisa & Inovacao Biodiversidade & Farmacos, Lab Quim Med & Computac, Ave Joao Dagnone 1100, BR-13563120 Sao Carlos, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
SBDD; FBDD; X-ray crystallography; NMR; Screening; Lead optimization; STRUCTURE-BASED DESIGN; X-RAY CRYSTALLOGRAPHY; NOVO LIGAND DESIGN; LEAD DISCOVERY; GLUCOSE COTRANSPORTER; MEDICINAL CHEMISTRY; PDE10A INHIBITORS; OPTIMIZATION; CANCER; SERIES;
D O I
10.2174/1568026617666170224113437
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fragment-based drug discovery (FBDD) is a broadly used strategy in structure-guided ligand design, whereby low-molecular weight hits move from lead-like to drug-like compounds. Over the past 15 years, an increasingly important role of the integration of these strategies into industrial and academic research platforms has been successfully established, allowing outstanding contributions to drug discovery. One important factor for the current prominence of FBDD is the better coverage of the chemical space provided by fragment-like libraries. The development of the field relies on two features: (i) the growing number of structurally characterized drug targets and (ii) the enormous chemical diversity available for experimental and virtual screenings. Indeed, fragment-based campaigns have contributed to address major challenges in lead optimization, such as the appropriate physicochemical profile of clinical candidates. This perspective paper outlines the usefulness and applications of FBDD approaches in medicinal chemistry and drug design.
引用
收藏
页码:2260 / 2270
页数:11
相关论文
共 50 条
  • [21] Fragment-based and structure-guided discovery of perforin inhibitors
    Jose, Jiney
    Law, Ruby H. P.
    Leung, Eleanor W. W.
    Wai, Dorothy C. C.
    Akhlaghi, Hedieh
    Chandrashekaran, Indu R.
    Caradoc-Davies, Tom T.
    Voskoboinik, Ilia
    Feutrill, John
    Middlemiss, David
    Jeevarajah, Devadharshini
    Bashtannyk-Puhalovich, Tanya
    Giddens, Anna C.
    Lee, Tet Woo
    Jamieson, Stephen M. F.
    Trapani, Joseph A.
    Whisstock, James C.
    Spicer, Julie A.
    Norton, Raymond S.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 261
  • [22] Application of Fragment-Based Drug Discovery to Versatile Targets
    Li, Qingxin
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [23] Fragment-based drug discovery using the SHAPES method
    Lepre, Christopher
    EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (12) : 1555 - 1566
  • [24] Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story
    Stamford, Andrew
    Strickland, Corey
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2013, 17 (03) : 320 - 328
  • [25] Native Mass Spectrometry in Fragment-Based Drug Discovery
    Pedro, Liliana
    Quinn, Ronald J.
    MOLECULES, 2016, 21 (08)
  • [26] In silico fragment-mapping method: a new tool for fragment-based/structure-based drug discovery
    Yamaotsu, Noriyuki
    Hirono, Shuichi
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2018, 32 (11) : 1229 - 1245
  • [27] A bright future for fragment-based drug discovery: what does it hold?
    Jacquemard, Celien
    Kellenberger, Esther
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (05) : 413 - 416
  • [28] Review of the impact of fragment-based drug design on PROTAC degrader discovery
    Chen, Peiqi
    Li, Qiang
    Lei, Xiaoguang
    TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2024, 171
  • [29] Using NMR Spectroscopy in the Fragment-Based Drug Discovery of Small-Molecule Anticancer Targeted Therapies
    Diethelm-Varela, Benjamin
    CHEMMEDCHEM, 2021, 16 (05) : 725 - 742
  • [30] Fragment-based Drug Discovery: Concept and Aim
    Tanaka, Daisuke
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2010, 130 (03): : 315 - 323